Live Breaking News & Updates on தலைகீழ் மருத்துவ தொழில்நுட்பம் இன்க்

Stay updated with breaking news from தலைகீழ் மருத்துவ தொழில்நுட்பம் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing


Share this article
Share this article
LONDON, Jan. 21, 2021 /PRNewswire/  LumiraDx, the next-generation point-of-care diagnostic testing company, announced today multinational approvals of its SARS-CoV-2 Antigen Test. With approvals in Japan and Brazil, the fast, accurate LumiraDx SARS-CoV-2 Antigen Test is now available to patients in more than 30 nations worldwide. In addition to these authorizations, the Italian Association for Clinical Microbiology recently published testing guidelines favorable to next-generation microfluidic technology – like LumiraDx s – for COVID-19 testing.
The LumiraDx SARS-CoV-2 Antigen Test is a microfluidic immunofluorescence assay designed to detect SARS-CoV-2 antigen in nasal or nasopharyngeal swab specimens, with high sensitivity results in 12 minutes from sample application. ....

United States , United Kingdom , North Lanarkshire , City Of , Dave Scott , Ron Zwanziger , Asia Pacific , Jerry Mcaleer , Italian Association For Clinical Microbiology , Medisense Inc , Melinda Gates Foundation , Alere Inc , Inverness Medical Technology Inc , Brazilian Health Regulatory Agency , Us Boston Capital Corporation , Italian Ministry Of Health , Devices Agency , Italian Association , Clinical Microbiology , Japan Pharmaceutical , Medical Devices Agency , Nacional De Vigil , Italian Ministry , Middle East , Lumiradx Platform , Emergency Use Authorization ,